SG10201803562YA - Amorphous magnesium-substituted calcium phosphate compositions and their uses - Google Patents
Amorphous magnesium-substituted calcium phosphate compositions and their usesInfo
- Publication number
- SG10201803562YA SG10201803562YA SG10201803562YA SG10201803562YA SG10201803562YA SG 10201803562Y A SG10201803562Y A SG 10201803562YA SG 10201803562Y A SG10201803562Y A SG 10201803562YA SG 10201803562Y A SG10201803562Y A SG 10201803562YA SG 10201803562Y A SG10201803562Y A SG 10201803562YA
- Authority
- SG
- Singapore
- Prior art keywords
- calcium phosphate
- amorphous magnesium
- substituted calcium
- phosphate compositions
- cargo
- Prior art date
Links
- -1 magnesium-substituted calcium phosphate Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1319548.2A GB201319548D0 (en) | 2013-11-05 | 2013-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201803562YA true SG10201803562YA (en) | 2018-06-28 |
Family
ID=49767709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803562YA SG10201803562YA (en) | 2013-11-05 | 2014-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| SG11201603261PA SG11201603261PA (en) | 2013-11-05 | 2014-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603261PA SG11201603261PA (en) | 2013-11-05 | 2014-11-05 | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10596122B2 (enExample) |
| EP (1) | EP3065715B1 (enExample) |
| JP (2) | JP2016537408A (enExample) |
| KR (1) | KR20160079060A (enExample) |
| CN (1) | CN105722504A (enExample) |
| AU (1) | AU2014345334B2 (enExample) |
| BR (1) | BR112016009809A2 (enExample) |
| CA (1) | CA2929123A1 (enExample) |
| EA (1) | EA201690659A1 (enExample) |
| ES (1) | ES2761559T3 (enExample) |
| GB (1) | GB201319548D0 (enExample) |
| IL (1) | IL245380B (enExample) |
| MX (1) | MX367473B (enExample) |
| SG (2) | SG10201803562YA (enExample) |
| WO (1) | WO2015067939A1 (enExample) |
| ZA (1) | ZA201602906B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| FR3021045B1 (fr) * | 2014-05-16 | 2020-02-21 | Solvay Sa | Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation |
| KR101893110B1 (ko) * | 2016-07-27 | 2018-08-31 | 삼일제약 주식회사 | 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제 |
| EP3538659A4 (en) * | 2016-11-09 | 2020-07-15 | Engene, Inc. | INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1 |
| CN110573455A (zh) * | 2017-04-27 | 2019-12-13 | 武礼伟仁株式会社 | 羟基磷灰石、化妆品和食品及其生产方法 |
| WO2021003601A1 (zh) * | 2019-07-05 | 2021-01-14 | 广州中大医疗器械有限公司 | 一种新型可载药微球及其制备方法 |
| WO2021086252A1 (en) | 2019-10-30 | 2021-05-06 | Psilox Ab | Stabilized amorphous calcium magnesium phosphate particle compositions |
| CN116768175B (zh) * | 2023-07-01 | 2025-12-19 | 常州市第二人民医院 | 高稳定性生物活性无定形磷酸钙镁的制备方法及应用 |
| KR20260019884A (ko) * | 2024-08-02 | 2026-02-10 | 한국과학기술연구원 | 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법 |
| CN118929595A (zh) * | 2024-08-30 | 2024-11-12 | 昆明理工大学 | 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| US6541037B1 (en) | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| EP1872798B1 (en) | 2005-04-06 | 2013-06-05 | Kabushiki Kaisha Sangi | Intestinal absorptive anti-tumor agent |
| EP2106217B1 (en) | 2006-12-12 | 2019-03-13 | Firmenich S.A. | Active ingredient delivery system with an amorphous metal salt as carrier |
| US20120128767A1 (en) * | 2008-05-01 | 2012-05-24 | Lee William W | Therapeutic calcium phosphate particles and methods of making and using same |
| GB201319548D0 (en) | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
-
2013
- 2013-11-05 GB GBGB1319548.2A patent/GB201319548D0/en not_active Ceased
-
2014
- 2014-11-05 ES ES14799845T patent/ES2761559T3/es active Active
- 2014-11-05 US US15/033,750 patent/US10596122B2/en not_active Expired - Fee Related
- 2014-11-05 MX MX2016005415A patent/MX367473B/es active IP Right Grant
- 2014-11-05 BR BR112016009809A patent/BR112016009809A2/pt not_active Application Discontinuation
- 2014-11-05 SG SG10201803562YA patent/SG10201803562YA/en unknown
- 2014-11-05 EA EA201690659A patent/EA201690659A1/ru unknown
- 2014-11-05 KR KR1020167014309A patent/KR20160079060A/ko not_active Ceased
- 2014-11-05 AU AU2014345334A patent/AU2014345334B2/en not_active Ceased
- 2014-11-05 SG SG11201603261PA patent/SG11201603261PA/en unknown
- 2014-11-05 WO PCT/GB2014/053291 patent/WO2015067939A1/en not_active Ceased
- 2014-11-05 CA CA2929123A patent/CA2929123A1/en not_active Abandoned
- 2014-11-05 JP JP2016551077A patent/JP2016537408A/ja active Pending
- 2014-11-05 EP EP14799845.4A patent/EP3065715B1/en not_active Not-in-force
- 2014-11-05 CN CN201480060734.7A patent/CN105722504A/zh active Pending
-
2016
- 2016-04-29 ZA ZA2016/02906A patent/ZA201602906B/en unknown
- 2016-05-01 IL IL245380A patent/IL245380B/en not_active IP Right Cessation
-
2019
- 2019-09-24 JP JP2019173127A patent/JP2020073467A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US10596122B2 (en) | 2020-03-24 |
| MX2016005415A (es) | 2017-03-01 |
| AU2014345334B2 (en) | 2019-10-31 |
| ZA201602906B (en) | 2019-09-25 |
| EA201690659A1 (ru) | 2016-10-31 |
| MX367473B (es) | 2019-08-23 |
| IL245380A0 (en) | 2016-06-30 |
| WO2015067939A1 (en) | 2015-05-14 |
| ES2761559T3 (es) | 2020-05-20 |
| US20160235683A1 (en) | 2016-08-18 |
| GB201319548D0 (en) | 2013-12-18 |
| IL245380B (en) | 2019-02-28 |
| KR20160079060A (ko) | 2016-07-05 |
| EP3065715B1 (en) | 2019-10-02 |
| AU2014345334A1 (en) | 2016-05-19 |
| JP2016537408A (ja) | 2016-12-01 |
| BR112016009809A2 (pt) | 2017-12-05 |
| EP3065715A1 (en) | 2016-09-14 |
| JP2020073467A (ja) | 2020-05-14 |
| CA2929123A1 (en) | 2015-05-14 |
| SG11201603261PA (en) | 2016-05-30 |
| CN105722504A (zh) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016005415A (es) | Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos. | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12017501583A1 (en) | Novel proteins specific for cd137 | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| IL257057A (en) | Biologically active peptides derived from soy for use in preparations and methods for wound healing, tissue engineering and regenerative medicine | |
| SG10201804306VA (en) | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MX2017010336A (es) | Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn. | |
| EA201391119A1 (ru) | Системы доставки наночастиц, их получение и применение | |
| MX2016001023A (es) | Formulaciones que contienen dapagliflozina amorfa. | |
| MX2013011421A (es) | Derivados de pirazolo-pirimidina. | |
| GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX376473B (es) | Composicion para tratar lesiones cerebrales. | |
| PH12017500018B1 (en) | Myo-inositol and probiotics, and their use | |
| MX368943B (es) | Formulaciones de tripeptido liofilizado estables en almacenamiento. | |
| GB2537783A (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
| MX2015001648A (es) | Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos. | |
| PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
| EP2902024A4 (en) | A SYNERGISTIC COMPOSITION OF NITAZOXANIDE AND MEANDAZOL, METHOD FOR THE PRODUCTION THEREOF AND USE OF THIS COMPOSITION FOR THE TREATMENT OF HUMAN PARASITES | |
| WO2014143763A3 (en) | Angiogenic compositions for wounds, articular joints and graft materials |